Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis

被引：0

作者：

Simpson, Eric ^{[1
]}

Boguniewicz, Mark ^{[2
,3
]}

Eichenfield, Lawrence ^{[4
]}

Gonzales, Mercedes E. ^{[5
]}

Hebert, Adelaide A. ^{[6
]}

Prajapati, Vimal H. ^{[7
,8
]}

Gooderham, Melinda ^{[9
,10
]}

Krupa, David ^{[11
]}

Chu, David H. ^{[11
]}

Higham, Robert C. ^{[11
]}

Berk, David R. ^{[11
]}

机构：

[1] Oregon Hlth & Sci Univ, Portland, OR USA

[2] Natl Jewish Hlth, Denver, CO USA

[3] Univ Colorado, Sch Med, Aurora, CO USA

[4] Univ Calif San Diego, Radys Childrens Hosp San Diego, San Diego, CA USA

[5] Pediat Skin Res LLC, Miami, FL USA

[6] UT Hlth, McGovern Med Sch, Houston, TX USA

[7] Skin Hlth Wellness Ctr, Dermatol Res Inst & Prob Med Res, Calgary, AB, Canada

[8] Univ Calgary, Calgary, AB, Canada

[9] SKiN Ctr Dermatol, Prob Med Res, Peterborough, ON, Canada

[10] Queens Univ, Peterborough, ON, Canada

[11] Arcutis Biotherapeut Inc, Westlake Village, CA USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷

关键词：

atopic dermatitis; efficacy; patient-reported outcomes; roflumilast cream; safety;

D O I：

10.1093/bjd/ljae266.022

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

641

引用

页数：1

共 50 条

[21] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials
Tofte, Susan J.
Papp, Kim
Sadick, Neil
Bohnert, Krista
Simpson, Eric
Thaci, Diamant
Bieber, Thomas
Blauvelt, Andrew
Sofen, Howard
Gooderham, Melinda
Chen, Zhen
Gadkari, Abhijit
Eckert, Laurent
Graham, Neil M. H.
Pirozzi, Gianluca
Ardeleanu, Marius
JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 (09): : 529 - 541
[22] Tapinarof cream 1% once daily: significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age
Silverberg, Jonathan, I
Eichenfield, Lawrence F.
Hebert, Adelaide A.
Simpson, Eric
Gold, Linda Stein
Bissonnette, Robert
Papp, Kim A.
Browning, John
Kwong, Pearl
Korman, Neil J.
Brown, Philip M.
Rubenstein, David S.
Piscitelli, Stephen C.
Somerville, Matthew C.
Tallman, Anna M.
Kircik, Leon
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II17 - II18
[23] Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials
Gold, Linda Stein
Del Rosso, James
Ehst, Benjamin D.
Zirwas, Matthew J.
Green, Lawrence J.
Brown, Philip M.
Rubenstein, David S.
Piscitelli, Stephen C.
Tallman, Anna M.
JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)
[24] Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies
Simpson, Eric L.
Augustin, Matthias
Thaci, Diamant
Misery, Laurent
Armstrong, April W.
Blauvelt, Andrew
Papp, Kim A.
Szepietowski, Jacek C.
Boguniewicz, Mark
Kwatra, Shawn G.
Kallender, Howard
Sturm, Daniel
Ren, Haobo
Kircik, Leon
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2025, 26 (01) : 121 - 137
[25] Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline patient demographics: Pooled subgroup analysis from two randomized phase 3 studies
Papp, Kim
Szepietowski, Jacek C.
Kircik, Leon
Toth, Darryl
Eichenfield, Lawrence F.
Forman, Seth B.
Armstrong, April W.
Kuligowski, Michael E.
Venturanza, May E.
Sun, Kang
Simpson, Eric L.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB149 - AB149
[26] Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% for treatment of chronic plaque psoriasis
Lebwohl, Mark
Gooderham, Melinda J.
Guenthner, Scott T.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB93 - AB93
[27] Efficacy and safety of once-daily roflumilast cream 0.3% in patients with knee/elbow involvement: Pooled results from phase 3 trials (DERMIS-1 and DERMIS-2)
Ferris, Laura K.
Draelos, Zoe D.
Hebert, Adelaide A.
Lynde, Charles W.
Pariser, David M.
Papp, Kim A.
Yamauchi, Paul S.
Feng, Amy
Higham, Robert C.
Burnett, Patrick
Berk, David R.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB162 - AB162
[28] Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by baseline body surface area
Gold, Linda Stein
Bagel, Jerry
Del Rosso, James
Green, Lawrence J.
Lebwohl, Mark
Kircik, Leon H.
Feng, Amy
Snyder, Scott
Higham, Robert C.
Burnett, Patrick
Berk, David R.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB192 - AB192
[29] Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials
Silverberg, Jonathan I.
Eichenfield, Lawrence F.
Hebert, Adelaide A.
Simpson, Eric L.
Gold, Linda Stein
Bissonnette, Robert
Papp, Kim A.
Browning, John
Kwong, Pearl
Korman, Neil J.
Brown, Philip M.
Rubenstein, David S.
Piscitelli, Stephen C.
Somerville, Matthew C.
Tallman, Anna M.
Kircik, Leon
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (03) : 457 - 465
[30] Efficacy and safety of roflumilast cream 0.3% in patients with chronic plaque psoriasis: pooled PASI and PASI-HD results from the DERMIS-1 and DERMIS-2 Phase 3 Trials
Papp, Kim
Lebwohl, Mark
Hong, H. Chih-ho
Kircik, Leon
Pariser, David
Strober, Bruce
Krueger, Gerald
Krupa, David
Burnett, Patrick
Berk, David
Higham, Robert
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB156 - AB156

← 1 2 3 4 5 →